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1. Introduction 
Systemic lupus erythematosus (SLE) is the most common multisystem connective tissue 
disease. It is characterised by a wide variety of clinical features and presence of numerous 
auto-antibodies, circulating immune complexes and widespread immunologically 
determined tissue damage [1]. Hematological abnormalities are common in SLE. All the 
cellular elements of the blood & coagulation pathway can be affected in SLE patients.  
The major hematological manifestations of SLE are anemia, leucopenia, thrombocytopenia, 
and antiphospholipid syndrome (APS). Hematological abnormalities in patients with this 
disease require careful long-term monitoring and prompt therapeutic intervention. 
Throughout the chapter we will analyze each abnormality, enumerate and explain the 
causes of each one and discuss an approach to the management. 
2. Anemia in systemic lupus erythematosus 
Anemia is found in about 50% of SLE patients, many mechanisms contribute to the 
development of anemia, including inflammation,  renal insufficiency,  blood loss,  dietary 
insufficiency, medications, haemolysis, infection, hypersplenism, myelofibrosis, 
myelodysplasia, and aplastic anemia that is suspected to have an autoimmune pathogenesis 
[2-9] table 1. 
2.1 Anemia of chronic disease 
A frequent cause of anemia in SLE is suppressed erythropoiesis from chronic 
inflammation (anemia of chronic disease or anemia of chronic inflammation), being the 
most common form (60 to 80 %) [5]. this type of anemia is normocytic and normochromic 
with a relatively low reticulocyte count. Although serum iron levels may be reduced, bone 
marrow iron stores are adequate and the serum ferritin concentration is elevated. In the 
absence of either symptoms attributable to anemia (eg: dyspnea on exertion, easy 
fatigability) or renal insufficiency, anemia of chronic inflammation does not require 
specific treatment. 
Patients with symptoms due to anemia of chronic inflammation, who have no other definite 
indication for glucocorticoid or other immunosuppressive therapy, may be given a trial of 
an agent that promotes erythropoiesis. The following two agents are an example: 
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Anemia of chronic disease 
Blood loss 
Gastrointestinal loss, menorrhagias 
Nutritional deficiencies 
Iron, folate, B12 
Immune mediated 
Haemolysis, red cell aplasia, haemophagocytosis, aplastic anaemia, pernicious anaemia 
Myelofibrosis 
Uremia 
Treatment induced 
Microangiopathic haemolysis 
Disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, drugs 
Hypersplenism 
Infection 
Myelodysplasia 
Table 1. Causes of anemia in patients with SLE 
 Epoetin alfa (recombinant human erythropoietin) 
 Darbepoetin alfa, a unique molecule that stimulates erythropoiesis with a longer half-
life than recombinant human erythropoietin.  
In one study that assessed the response to erythropoietin in patients with SLE and anemia of 
chronic inflammation, 58 percent had an adequate response to erythropoietin 
supplementation [7]. 
Patients who are symptomatically anemic, having signs of active inflammations, and do not 
respond to an agent that promotes erythropoiesis, often improve when glucocorticoids are 
used in high doses(1 mg/kg per day of prednisone or its equivalent in divided doses). If, after 
approximately one month of treatment, the response is unsatisfactory (eg, hemoglobin still <11 
g/dL) the dose of glucocorticoids should be rapidly reduced, and discontinued if there is no 
other indication for their use. If there is a response, the dose should be tapered as rapidly as to 
possible to the lowest dose that maintains the improvement.  Immunosuppressive agents also 
may help, but carry a risk of further bone marrow suppression. 
2.2 Renal insufficiency 
An inappropriately low level of erythropoietin is a hallmark of anemia due to renal 
insufficiency. The primary cause of anemia in this setting is typically deficient production of 
erythropoietin by the diseased kidneys. In the patient with SLE, anemia, and renal 
insufficiency who does not have other evidence of active inflammation, administration of 
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erythropoiesis-stimulating agents may be indicated when the anemia is causing symptoms 
or the hemoglobin concentration is <11 gm/dL. 
2.3 Iron deficiency anemia 
Anemia may reflect acute or chronic blood loss from the gastrointestinal tract, usually 
secondary to medications (nonsteroidal antiinflammatory drugs or steroids), or may be due 
to excessive menstrual bleeding. Iron deficiency anemia is not uncommon, especially among 
teenagers or young women. Long-term anemia of chronic inflammation can also lead to iron 
deficiency, since, hepcidin, the key inducer of the anemia of chronic inflammation, inhibits 
iron absorption from the gastrointestinal tract. 
Pulmonary hemorrhage is a rare cause of anemia in SLE. Not all patients have hemoptysis. 
Other symptoms of alveolar hemorrhage are dyspnea and cough. The presence of alveolar 
infiltrates on a chest radiograph or ground-glass opacities on chest CT are suggestive of 
alveolar hemorrhage.  
2.4 Red cell aplasia 
Red cell aplasia, probably due to antibodies directed against either erythropoietin or bone 
marrow erythroblasts, has been observed, although it is rare [5,6,10]. This form of anemia 
usually responds to steroids, although cyclophosphamide and cyclosporine have been 
successfully employed.  
Even rarer are isolated case reports of aplastic anemia, presumably mediated by auto 
antibodies against bone marrow precursors; immunosuppressive therapy also may be 
effective in this setting [11-13]. 
In addition, bone marrow suppression can also be induced by medications, including 
antimalarials and immunosuppressive drugs. 
2.5 Autoimmune hemolytic anemia 
Overt autoimmune hemolytic anemia (AIHA), characterized by an elevated reticulocyte 
count, low haptoglobin levels, increased indirect bilirubin concentration, and a positive 
direct Coombs' test, has been noted in up to 10 percent of patients with SLE [2-4,8,14]. The 
presence of hemolytic anemia may be associated with other manifestations of severe disease 
such as renal disease, seizures, and serositis [14]. 
Other patients have a positive Coombs' test without evidence of overt hemolysis. The 
presence of both immunoglobulin and complement on the red cell is usually associated with 
some degree of hemolysis, while the presence of complement alone (eg, C3 and/or C4) is 
often not associated with hemolysis [1-4].  
AIHA responds to steroids (1 mg/kg per day of prednisone or its equivalent in divided 
doses) in 75 to 96 percent of patients [15, 16]. Once the hematocrit begins to rise and the 
reticulocyte count falls, steroids can be rapidly tapered. If there is no response, we can 
consider pulse steroids (eg,1000 mg methylprednisolone intravenously daily for three days) 
[15], azathioprine (up to 2 mg/kg per day) [17], cyclophosphamide (up to 2 mg/kg) [18], or 
splenectomy. Success rates for splenectomy as high as 60 percent have been reported [19], 
although others have found no benefit [20]. 
Other described approaches to patients with refractory AIHA include intravenous immune 
globulin [18], danazol [21-23], mycophenolate mofetil [24], and rituximab [25]. 
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2.6 Microangiopathic hemolytic anemia 
Lupus has also been associated with a thrombotic microangiopathic hemolytic anemia 
[26] as manifested by a peripheral blood smear showing schistocytes and elevated serum 
levels of lactate dehydrogenase (LDH) and bilirubin. Many affected patients also have 
thrombocytopenia, kidney involvement, fever, and neurologic symptoms. This pentad of 
features is compatible with a diagnosis of thrombotic thrombocytopenic purpura (TTP). 
However, the pathogenesis of TTP in these patients is likely heterogeneous, as it may reflect 
vasculitis or antiphospholipid syndrome as well [27, 28]. 
Whether the occurrence of both SLE and TTP in an individual patient is a coincidence or 
represents a true association is an unsettled question. 
Other patients with microangiopathic red cell destruction do not have fever or neurologic 
disease, producing a pattern of hemolytic-uremic syndrome. The pathogenesis of this 
syndrome is not completely understood. In one report of 4 patients plus 24 others identified 
from a literature review, antiphospholipid antibodies (aPL) were searched for in eight and 
found in five [26]. 
The presence of aPL in SLE patients with severe hemolytic anemia, renal dysfunction, and 
central nervous system involvement has also been reported [31].  
In a review of 28 reported patients, those treated with plasma infusions or plasmapheresis, 
glucocorticoids alone, or no therapy had mortality rates of 25, 50, and 100 percent, 
respectively [26]. However, in another series of 15 patients with SLE and microangiopathic 
hemolytic anemia, all responded to treatment with high-dose glucocorticoids and none were 
treated with plasmapheresis [32]. In a retrospective study [27] in which 70 percent of 
patients with SLE and TTP underwent plasma exchange, the response rate of 74 percent was 
comparable to that observed in patients with idiopathic TTP. 
Patients with SLE, severe microangiopathic hemolytic anemia, and other major organ 
dysfunction should be treated with plasmapheresis and plasma infusion as in other cases of 
thrombotic thrombocytopenic purpura or the hemolytic-uremic syndrome. Those with less 
severe disease may be treated with high-dose glucocorticoids and observed carefully with 
the addition of plasmapheresis should they deteriorate or fail to improve with steroid 
treatment alone. 
3. An approach to lupus patient with anaemia 
After the detailed analysis and discussion of each type of anemia associated with SLE, here 
is a simple approach to anemic SLE patient with an easy mechanism to the diagnosis. 
Anaemia can be divided into those conditions with impaired red cell production (marrow 
suppression, nutrient deficiency) and those with increased red cell destruction (haemolysis, 
hypersplenism) or blood loss. Measurement of reticulocyte production (reticulocyte index) 
usually used to make this distinction and it is the major step for determination of causes of 
anaemia. IDA is defined by serum ferritin level below: 20 μg/dl. Pernicious anemia (PA) is 
defined by serum vitamin B12 of less than: 180 pmol/l together with one or more of the 
following: an abnormal Schilling test result or the presence of anti-intrinsic factor antibody 
in the blood.  
It is also important to mention that the examination of the peripheral blood smear is a 
mandatory step in the initial evaluation of all SLE patients with hematologic disorders. The 
examination of blood films stained with Wright's stain frequently provides important clues 
in the diagnosis of anemias and various disorders of leukocytes and platelets and we can 
www.intechopen.com
 
Haematological Manifestations in Systemic Lupus Erythematosus 367 
discover a life threatening conditions like TTP early on. For example, some of the 
abnormalities suspicious for the presence of hemolysis in blood smear include the following: 
 Spherocytes (microspherocytes and elliptocytes) indicate autoimmune hemolytic anemia 
 Fragmented RBC (schistocytes, helmet cells) indicating the presence of 
microangiopathic hemolytic anemia ( thrombotic thrombocytopenic purpura-hemolytic 
uremic syndrome )  
 Acanthocytes (spur cells) in patients with liver disease. 
 Blister or "bite" cells due to the presence of oxidant-induced damage to the red cell and 
its membrane (G-6-PD).  
 RBCs with inclusions, as in malaria, babesiosis, and Bartonella infections (" non-
immune hemolytic anemia due to systemic disease", ''). 
 Teardrop RBCs with circulating nucleated RBC and early white blood cell forms, 
indicating the presence of marrow involvement, as in primary myelofibrosis or tumor 
infiltration. 
So at a practical level, when you are faced with SLE anaemia, it will be easy to differentiate 
among the possible mechanisms with only a few tests. If the reticulocytes are increased, a 
haemolytic process or acute bleeding should be the probable cause. If the reticulocytes are 
inadequate, you should rule out a nutritional deficiency of iron, vitamin B12, or folate. 
Ferritin determination suffices for diagnosing IDA. If the ferritin concentration is greater 
than 20 μg/dl, IDA is virtually never present and a bone marrow examination may be 
considered, but we have to mention that ferritin is an acute phase reactant and it can be 
elevated in any patients with inflammatory process due to any cause, although the 
diagnostic yield may be very low and anaemia of chronic disease is the most common 
diagnosis of exclusion (figure 1). 
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4. Leukopenia in systemic lupus erythematosus 
Leukopenia is common in SLE and usually reflects disease activity. A white blood cell count 
of less than 4500/microL has been noted in approximately 50 percent of patients, especially 
those with active disease [3, 4], while lymphocytopenia occurs in approximately 20 percent 
[3]. In comparison, a white blood cell count below 4000/microL (an American College of 
Rheumatology criterion for SLE) occurs in only 15 to 20 percent of patients [3, 33]. 
Neutropenia, lymphocytopenia, and decreased circulating eosinophils and basophils may 
all contribute to leukopenia. 
4.1 Neutropenia 
Neutropenia in patients with SLE can result from: immune mechanisms, medications (eg, 
cyclophosphamide or azathioprine), bone marrow dysfunction, or hypersplenism [3,4,33,34]. 
Other clinical features that may be associated with moderate to severe neutropenia (absolute 
neutrophils <1000/microL) include infection, anemia, thrombocytopenia, and a history of 
neuropsychiatric involvement [34]. 
4.2 Lymphocytopenia 
Lymphocytopenia (lymphocytes less than 1500/microL), especially involving suppressor  
T cells, has been observed in 20 to 75 percent of patients, particularly during active disease  
[1-3, 37, 38]. This finding is strongly associated with IgM, cold reactive, complement fixing, 
and presumably cytotoxic antilymphocyte antibodies; such antibodies were noted in 26 of  
29 patients with SLE and the antibody titer correlated directly with the degree of lymphopenia 
[39]. 
4.3 Decreased eosinophils and basophils 
Steroid therapy may result in low absolute eosinophil and monocyte counts [41]. The 
number of basophils may also be decreased in SLE, particularly during active disease  
[42].  
4.4 Leukopenia  
In SLE rarely needs treatment. An exception is the patient with neutropenia and recurrent 
pyogenic infections. One problem is the toxicity of the usual therapies. Prednisone (10 to 60 
mg/day) can raise the white blood cell count but can also result in an increased risk  
of infections; immunosuppressive agents such as azathioprine or cyclophosphamide have 
the potential to cause worsening of the leukopenia via bone marrow suppression, 
respectively [43]. 
Cautious use of azathioprine, with careful monitoring of the white blood cell count, may be 
considered in this setting. 
5. Leukocytosis in systemic lupus erythematosus 
Leukocytosis (mostly granulocytes) can occur in SLE. When present, it is usually due to 
infection or the use of high doses of glucocorticoids [43], but may occur during acute 
exacerbations of SLE. A shift of granulocytes to more immature forms (a "left" shift) suggests 
infection. 
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6. Thrombocytopenia in systemic lupus erythematosus  
Mild thrombocytopenia (platelet counts between 100,000 and 150,000/microL) has been 
noted in 25 to 50 percent of patients; while counts of less than 50,000/microL occur in only 
10 percent [1, 3,4,33]. There are several potential causes of thrombocytopenia in patients 
with SLE. Immune mediated platelet destruction is most often the cause, but platelet 
consumption may also occur in association with microangiopathic hemolytic anemia (see 
'Microangiopathic hemolytic anemia' above) or could be due to impaired platelet production 
as a result of the use of cytotoxic, immunosuppressive, or other drugs. 
The major mechanism is immunoglobulin binding to platelets followed by phagocytosis in 
the spleen, as in idiopathic thrombocytopenic purpura (ITP) [47]. Membrane glycoproteins 
(GP) are most often the target of such antibodies (eg, GP IIb/IIIa) but anti-HLA specificity 
also occurs [48]. 
Antigen-dependent B cell development in lymphoid tissues is influenced by binding of 
CD40 on B cells to CD40-ligand on activated T cells. The finding of autoantibodies to CD40-
ligand in patients with SLE, APS, and ITP, but not in the serum of healthy blood donors 
suggests that interference with T cell and B cell interaction may play a role in the 
development of thrombocytopenia [49]. 
Other important mechanisms in selected patients include bone marrow suppression by 
immunosuppressive drugs (other than corticosteroids), increased consumption due to a 
thrombotic thrombocytopenic purpura [TTP] [26], the antiphospholipid syndrome, or 
antibodies that block the thrombopoietin receptor on megakaryocytes or their precursors.  
ITP may be the first sign of SLE, followed by other symptoms as long as many years later. It 
has been estimated that 3 to 15 percent of patients with apparently isolated ITP go on to 
develop SLE [50].  
Evans syndrome (ie, both autoimmune thrombocytopenia and autoimmune hemolytic 
anemia) also may precede the onset of SLE. Severe bleeding from thrombocytopenia is only 
experienced by a minority of patients; however, SLE patients with thrombocytopenia are 
more likely to have associated significant organ damage, such as heart and kidneys and the 
CNS [51]. 
6.1 Medical therapy 
Platelet counts between 50,000/microL and 20,000/microL rarely cause more than a 
prolonged bleeding time, while counts of less than 20,000/microL may be associated with 
petechiae, purpura, ecchymoses, epistaxis, gingival, and other clinical bleeding.  
Treatment of thrombocytopenia is usually recommended for symptomatic patients with 
counts of less than 50,000/microL and for all patients with counts of less than 
20,000/microL. 
The treatment of ITP in SLE is the same as that in patients without lupus. 
Briefly, the mainstay of treatment is glucocorticoid therapy. Older studies used prednisone 
(1 mg/kg per day in divided doses) [54, 55]. However, treatment with four to eight cycles of 
oral high dose dexamethasone (40 mg per day for four days) at intervals of two weeks to 
four weeks may result in similar remission rates and better long-term responses than those 
observed in historical controls treated with daily prednisone [56]. 
Most patients respond to glucocorticoid therapy within one to eight weeks [57]. If there is no 
significant increase in the platelet count within one to three weeks or side effects are 
intolerable, the following options may be considered and used depends upon the severity of 
the thrombocytopenia and the presence or absence of other manifestations of SLE: 
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 Azathioprine  
 Cyclophosphamide [58].  
 Intravenous immune globulin is very effective and may be preferred to azathioprine or 
cyclophosphamide when a rapid rise in platelet count is necessary (as in the patient 
who is actively bleeding or requires emergent surgery) [59]. 
 Mycophenolate mofetil may be useful in the patient refractory to other medical therapy 
[60]. 
 Rituximab has been used to treat ITP in patients without SLE who were refractory to 
other treatments and this B lymphocyte depleting approach may be beneficial for other 
manifestations of lupus [25].  
6.2 Splenectomy 
Splenectomy can raise the platelet count but it does not reliably produce a durable remission 
of thrombocytopenia. Relapse following splenectomy may occur and has been noted at 
varying times from 1 to 54 months after surgery [62]. 
6.3 Thrombocytopenia following splenectomy 
Patients with persistent thrombocytopenia after splenectomy may subsequently respond to 
azathioprine, cyclophosphamide, rituximab, intravenous immunoglobulin, or danazol 
[23,63,64]. If possible, splenectomy should be preceded by immunization with 
pneumococcal vaccine to reduce the risk of pneumococcal sepsis. 
7. Thrombocytosis in systemic lupus erythematosus 
Thrombocytosis is a less frequent finding in patients with SLE and it might be occurring as 
an acute phase reactant and a sign of active disease.  
8. Pancytopenia in systemic lupus erythematosus 
Although peripheral destruction of red cells, leukocytes, and platelets may occur together 
and lead to clinically significant pancytopenia, depression of all three cell lines also suggests 
bone marrow failure, as in the case in aplastic anemia. Thus, bone marrow examination is 
the most important diagnostic test to perform.  
Causes of marrow failure include drugs and coincidental diseases including: the acute 
leukemias, large granular lymphocyte leukemia, the myelodysplastic syndromes, marrow 
replacement by fibrosis or tumor, severe megaloblastic anemia, paroxysmal nocturnal 
hemoglobinuria (PNH), and overwhelming infection. In addition, unexplained cytopenia 
can be associated with bone marrow necrosis, dysplasia, and distortion of the bone marrow 
architecture [70]. 
Among patients with SLE an unusual cause of pancytopenia is the macrophage activation 
syndrome. The clinical characteristics of 12 patients with SLE-associated macrophage 
activation syndrome included [71]: 
Fever (100%), weight loss (80%), arthritis (50%), pericarditis (42%), rash (66%) myocarditis 
(33%), nephritis (33%), splenomegaly (27%), hepatomegaly (13%), lymphadenopathy(73%), 
anemia (100%), leukopenia (87%), hyperferritinemia (100%), anti-DNA antibodies (80%),low 
CRP (<30 mg/L) (90%), hypocomplementemia (60%). 
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The demonstration of hemophagocytosis in the bone marrow or in material obtained from 
peripheral lymph nodes is a characteristic finding. 
The few reported cases of macrophage activation syndrome in patients with SLE have 
usually responded to treatment with glucocorticoids and immunosuppressive agents. 
Optimal treatment is uncertain.  
9. Lymphadenopathy and splenomegaly in systemic lupus erythematosus 
Enlargement of lymph nodes occurs in approximately 50 percent of patients with SLE. The 
nodes are typically soft, nontender, discrete, varying in size from 0.5 to several centimeters, 
and usually detected in the cervical, axillary, and inguinal areas. Lymphadenopathy is more 
frequently noted at the onset of disease or in association with an exacerbation. Biopsies 
reveal areas of follicular hyperplasia and necrosis, the appearance of hematoxylin bodies is 
highly suggestive of SLE, although unusual [1]. 
Lymph node enlargement can also be due to infection or a lymphoproliferative disease in 
SLE. When infections are present, the enlarged nodes are more likely to be tender. 
Prominent lymphadenopathy may also be a manifestation of angioimmunoblastic T cell 
lymphoma. This disorder has other clinical features (arthritis, Coombs-positive hemolytic 
anemia, skin rash, fever, and weight loss) that are suggestive of systemic lupus 
erythematosus or systemic onset juvenile rheumatoid arthritis (Still's disease). Enlargement 
of the spleen occurs in 10 to 46 percent of patients, particularly during active disease. 
Splenomegaly is not necessarily associated with a cytopenia. Pathologic examination of 
spleen reveals an onion skin appearance of the splenic arteries, a lesion that is thought to 
represent healed vasculitis. 
In view of the frequent presence of lymphadenopathy and splenomegaly in SLE, the 
possibility of a lymphoproliferative malignancy may be considered. The risk of non-
Hodgkin lymphoma appears to be increased four- to five fold in patients with lupus. 
A lymph node biopsy may be warranted when the degree of lymphadenopathy is out of 
proportion to the activity of the lupus. 
One of the rare diseases that reported to be associated with SLE is: 
9.1 Kikuchi-Fujimoto’s disease (KFD) 
Also called histiocytic necrotizing lymphadenitis which is a rare benign and self limited 
disease, of unknown etiology, affects mainly young women [77]. It presents with localized 
lymphadenopathy, predominantly in the cervical region, less commonly include axillary 
and mesenteric lymphadenopathy accompanied by fever and leucopenia in up to 50% of the 
cases [78, 79]. KFD has been reported in association with systemic lupus erythematosus 
(SLE), the relation between Kikuchi’s disease and SLE is not yet completely understood and 
remains complex. The reports imply that SLE may be present before, at the same time, or 
after the clinical appearance of KFD [77-79]. 
KFD can be a complication of prolonged and multiple immunosuppressant use in SLE 
patients, There is a published case report in 2011 of KFD that diagnosed based on a lymph 
node biopsy in a 31 year old Saudi female patient with an established diagnosis of stage IV 
lupus nephritis. She presented with fever, axillary lymphadenopathy and neutropenia. The 
patient is known to have SLE for 16 years prior to the presentation with history of 
prolonged use of many immunosuppressive medications. The patient treated with 
intravenous antibiotic as a case of febrile neutropenia and recovered spontaneously. They 
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concluded that in most of the cases the diagnosis of KFD was made before or at the same 
time of the diagnosis of SLE. In this case report the diagnosis of KFD was made years after 
the diagnosis of SLE. They also noted that the patient received prolonged courses of 
immunosuppressant medications including mycophenolate mofetil, and then 6 cycles of 
cyclophosphamide, she was placed then on azothioprine and hydroxychloroquine. So they 
consider the prolonged use of immunosuppressant medications a risk factor for KFD in a 
well established SLE with lupus nephritis.  
10. Antibodies to clotting factors and anti-phospholipids syndrome in 
systemic lupus erythematosus 
Antibodies to a number of clotting factors, including VIII, IX, XI, XII, and XIII have been 
noted in patients with SLE [1,2,33]. These antibodies may not only cause abnormalities of in 
vitro coagulation tests but may also cause bleeding.  
Much more common are aPL (antiphospholipid antibodies), the presence of which has been 
associated with a prolongation of the partial thromboplastin time (PTT) (lupus 
anticoagulant activity) and an increased risk of arterial and venous thrombosis, 
thrombocytopenia, and fetal loss [72, 73]. Antibodies to other phospholipids and to 
phospholipid binding proteins (eg, anticardiolipin antibodies) in moderate or high levels 
may also be associated with these clinical phenomena. When aPL occurs in association with 
one or more of these clinical features in a patient with SLE it suggests the presence of  
the APS.  
10.1 Antiphospholipid syndrome 
The antiphospholipid syndrome (APS) is defined by two major components:  
1. The occurrence of at least one clinical feature: vascular event or pregnancy morbidity 
AND  
2. The presence of at least one type of autoantibody known as an antiphospholipid 
antibody (aPL). 
In addition, there are aPL-related clinical manifestations that are not part of the APS 
Classification Criteria, such as livedo reticularis, thrombocytopenia, cardiac valve disease, or 
aPL-nephropathy. 
APL is directed against serum proteins bound to anionic phospholipids and may be 
detected by a: Lupus anticoagulant tests, Anticardiolipin antibody ELISA and Anti-ß2 
glycoprotein-I ELISA. 
The full clinical significance of other autoantibodies, including those directed against 
prothrombin, annexin V, phosphatidylserine, and phosphatidylinositol, remain unclear. 
APS occurs as a primary condition or in the setting of an underlying systemic autoimmune 
disease, particularly SLE [72]. 
 Classification criteria have been developed for research purposes. They may be helpful 
to clinicians, but not all the classification criteria need to be met to make a clinical 
diagnosis of APS.  
Definite APS is considered present if at least one of the following clinical criteria and at least 
one of the following laboratory criteria are satisfied: 
 Clinical: one or more episodes of venous, arterial, or small vessel thrombosis and/or 
morbidity with pregnancy. 
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 Thrombosis: unequivocal imaging or histological evidence of thrombosis in any tissue 
or organ, OR  
 Pregnancy morbidity : otherwise unexplained death at ≥10 weeks gestation of a 
morphologically normal fetus, OR  
 One or more premature births before 34 weeks of gestation because of eclampsia, 
preeclampsia, or placental insufficiency, OR  
 Three or more embryonic (<10 week gestation) pregnancy losses unexplained by 
maternal or paternal chromosomal abnormalities or maternal anatomic or hormonal 
causes. 
 Laboratory : the presence of aPL, on two or more occasions at least 12 weeks apart and 
no more than five years prior to clinical manifestations, as demonstrated by one or more 
of the following: IgG and/or IgM aCL in moderate or high titer), antibodies to ß2-GP-I 
of IgG or IgM isotype at a high titer. LA activity detected according to published 
guidelines [72, 75]. 
10.1.1 Pathology 
The characteristic pathologic finding in the APS is a bland thrombosis with minimal 
vascular or perivascular inflammation. This change is not specific for the APS, as it also 
occurs in the kidney in a variety of other disorders including the hemolytic-uremic 
syndrome/thrombotic thrombocytopenic purpura, systemic sclerosis (scleroderma), and 
malignant hypertension. Larger vessels, both arteries and veins, may develop in situ 
thrombosis or be sites from or into which emboli originate or lodge. 
10.1.2 Clinically 
 The APS is characterized by venous or arterial thromboses, morbidity occurring in the 
setting of pregnancy, and/or aPL-related clinical manifestations that are not part of the 
APS Classification Criteria, such as livedo reticularis, thrombocytopenia, cardiac valve 
disease, or aPL-nephropathy [73, 74]. 
In a series of 1000 patients with either primary or secondary APS, the various disease 
features were [74]: 
Deep vein thrombosis (32%), Thrombocytopenia (22%), Livedo reticularis (20%), Stroke 
(13%), Superficial thrombophlebitis (9%), Pulmonary embolism (9%), Fetal loss (8 %), TIA 
(7%), Hemolytic anemia (7%). 
In rare patients, APS results in multi-organ failure because of multiple blood vessel 
occlusions, a condition referred to as "catastrophic antiphospholipid syndrome".  
In addition to those already mentioned above, other possible aPL-related clinical 
manifestations include migraine headache, Reynaud phenomenon, pulmonary 
hypertension, avascular necrosis, cutaneous ulcers that resemble pyoderma gangrenosum, 
adrenal insufficiency due to hemorrhagic infarction, and cognitive deficits [72-75].  
 Thrombosis: the risk of both venous and arterial thrombosis and/or thromboembolism 
is increased in individuals with positive tests for LA activity or medium or high levels 
of aCL. The risk of recurrent thrombosis or thromboembolism may be further enhanced 
in those with positivity to three aPL activities (LA, aCL, and ß2-glycoprotein-I) upon 
repeated testing [74]. 
Initial site: venous thromboses are more common than arterial thromboses in the APS [73, 
74]. The most common site of DVT is the calf, but the renal veins, the hepatic, axillary, 
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subclavian, and retinal veins, the cerebral sinuses, and the vena cava may also be involved. 
The most common site of arterial thrombosis is the cerebral vessels, but coronary, renal, and 
mesenteric arteries and arterial bypass graft occlusions have also been noted. 
To some degree, the site of thrombosis may be related to the type of aPL present. This was 
illustrated in a retrospective study of 637 patients with APS in which DVT and PE were 
more frequent among patients with LA, while coronary, cerebrovascular, and peripheral 
arterial events were more likely in those with elevated levels of IgG or IgM aCL. 
 Deep venous thrombosis: APL can be detected in approximately 5 to 21 percent of all 
patients with DVT [72]. The incidence of DVT may correlate with the level of aCL. As 
an example, one study found that DVT occurred in 44% of patients with high titers of 
aCL, in 29% with low titers, and in only 10% of those without these antibodies [73]. 
Stroke: the APS is strongly linked to ischemic stroke [74, 80]. The occurrence of livedo 
reticularis in association with a stroke is known as Sneddon's syndrome [73]. In the great 
majority of cases, Sneddon's syndrome is associated with detectable aPL. 
A thrombotic stroke occurring in a young patient with no overt risk factors for cerebrovascular 
disease is the classic setting to suspect the APS. In one study, aPL was found in 25% of patients 
younger than 45 years of age who presented with a stroke of unclear etiology [81]. In another 
report, 20 percent of stroke victims under the age of 50 had aPL [74]. Ischemic stroke may be a 
manifestation in situ thrombosis or due to embolism arising from a valvular heart disease. If 
routine transthoracic echocardiography is normal, transesophageal echo may be indicated to 
assess for vegetations due to nonbacterial endocarditis. 
Several studies have evaluated the risk of stroke associated with the presence of aPL: 
In a review of 2000 healthy male subjects, the relative risk of stroke at 15 years of follow-up 
was 2.2 in subjects with aPL []. Events were observed primarily in subjects who had both ß2-
GP-I and IgG aCL (ie, ß2-GP-I dependent aCL).  
In the Stroke Prevention in Young Women study, the presence of LAs and aCL was 
evaluated in 160 cases and 340 controls [74]. After adjustment for potential confounders, the 
relative odds of stroke for women with an aCL of any isotype or an LA was 1.87 (95% CI 1.2 
to 2.8). Similar findings of an increased risk of ischemic stroke associated with aCL limited 
to women were noted in a report from the Framingham Cohort and Offspring Study 
(hazard ratio for women 2.6; 95% CI 1.3 to 5.4) [73]. 
Neurologic syndromes besides stroke: strong associations are now recognized between the 
presence of aPL and the occurrence of cognitive deficits and/or white matter lesions. 
However, the link with the APS is less strong for other neurological associations. 
White matter lesions: see chapter of neurology in SLE. 
Other neurological associations: epilepsy, depression, psychosis, chorea and hemiballismus, 
transverse myelopathy, sensorineural hearing loss, orthostatic hypotension, migraine. 
Recurrent thrombotic events: are common in APS. Most but not all observers have noted 
that an initial arterial thrombosis tends to be followed by an arterial event, and that an initial 
venous thrombosis is usually followed by a venous event [72]. 
Pregnancy loss and preeclampsia: the presence of APS may be related to several types of 
morbidity during pregnancy. These include fetal death after 10 weeks gestation, premature 
birth due to severe preeclampsia or placental insufficiency, or multiple embryonic losses 
(<10 weeks gestation).  
In patients with preeclampsia or HELLP syndrome, the possibility of the catastrophic APS 
must be considered, particularly in patients with histories of thrombosis or spontaneous 
abortions [73]. 
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Hematologic manifestations: prominent hematologic manifestations of APS include 
thrombocytopenia, microangiopathic hemolytic anemia and, in rare cases, bleeding: 
Thrombocytopenia: a review of 13 studies of 869 patients with SLE, found that 
thrombocytopenia was more common in those with LA (55 percent) and aCL (29 PERCENT) 
than in those without these antibodies [50]. Conversely, patients with thrombocytopenia 
associated with autoimmune disorders frequently have aPL (eg, 70 to 82 percent of patients 
with SLE and thrombocytopenia, and 30 to 40 percent of those with ITP [26, 49, 50]. 
Thrombotic microangiopathy: APL has been implicated in some cases of TTP/HUS that 
occur in SLE. See hematological manifestations in SLE. 
Bleeding episodes: the presence of antibodies to prothrombin should be suspected when a 
patient with a known LA also has a low prothrombin level and develops bleeding 
complications rather than thrombosis. 
Pulmonary disease: pulmonary embolism occurs in approximately one-third of patients 
with the APS who develop DVT. Other recognized pulmonary complications of the APS 
include [26, 48-50]: Pulmonary arterial thrombosis with or without thromboembolic 
pulmonary hypertension and alveolar hemorrhage.  
In addition, fibrosing alveolitis, adult respiratory distress syndrome, and 
nonthromboembolic pulmonary hypertension have been reported in association with aPL 
[50, 72]. However, the relationship to these disorders to aPL is unclear 
Cardiovascular disease: patients with aPL commonly have cardiac disease, including 
valvular thickening, mitral valve nodules, and nonbacterial vegetations. Involvement of the 
mitral and aortic valves can lead to valvular regurgitation and rarely to stenosis. 
APL have also been incriminated in intracardiac thrombi, pericardial effusion, 
cardiomyopathy, emboli in those with or without infective endocarditis, premature 
restenosis of vein grafts for coronary bypass, and peripheral vascular disease [50].  
Cutaneous: APL has been associated with many cutaneous abnormalities including splinter 
hemorrhages, livedo reticularis, cutaneous necrosis and infarction, [49, 50]. 
Gastrointestinal disease: patients with aPL may have ischemia involving the esophagus, 
stomach, duodenum, jejunum, ileum, or colon resulting in gastrointestinal bleeding, 
abdominal pain, an acute abdomen, esophageal necrosis with perforation, or giant gastric or 
atypical duodenal ulceration [73]. Splenic or pancreatic infarction may also occur. In 
addition, the liver may involved; hepatic or portal venous thrombosis may result in the 
Budd-Chiari syndrome, hepatic-veno-occlusive disease, hepatic infarction, portal 
hypertension, and cirrhosis. [72]. 
Ocular manifestations: amaurosis fugax, retinal venous and arterial occlusion, and anterior 
ischemic optic neuropathy have occurred in patients with aPL [72].  
Catastrophic APS: a small subset of patients with APS has widespread thrombotic disease 
with multiorgan failure, which is called "catastrophic APS." Preliminary criteria proposed 
for classification .purposes have been published and validated (Among 1000 patients with 
the APS followed for a mean of seven years, only 8 (0.8 percent) developed catastrophic APS 
[73, 74]. In the majority of these patients, multiorgan involvement was present at the time of 
diagnosis of APS. 
Patients with catastrophic APS may have laboratory features such as elevated fibrin 
degradation products, depressed fibrinogen levels, or elevated D-dimer concentrations that 
are more typically found with disseminated intravascular coagulation (DIC). 
Catastrophic APS is frequently fatal, with a reported mortality rate approaching 50 percent 
despite anticoagulant and immunosuppressive treatment [74]. 
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10.1.3 Primary APS versus SLE 
The antiphospholipid syndrome was first described as a complication of the disease ‘SLE’. 
However, in many cases – indeed probably the vast majority did NOT have any evidence of 
lupus. This gave rise to the term ‘Primary Antiphospholipid Syndrome’ (PAPS).  
For those patients where the clotting tendency is secondary to another disease such as 
lupus, the condition is often called ‘Secondary Anitphospholipid Syndrome'.  
It should be stressed that the majority of patients with ‘Primary’ APS (Hughes Syndrome) 
do NOT go on to develop lupus in later life. The inter-relationship between lupus and APS 
(Hughes Syndrome) is highlighted in this diagram below:  
 
 
 
some data suggest that the clinical manifestations of primary APS and APS associated with 
SLE are similar [73]. In contrast, a subsequent study of 122 patients noted that the frequency 
of arterial thromboses, venous thromboses, and fetal loss was greater in patients with APS 
and SLE than in those with primary APS [72]. 
A separate issue is the frequency of evolution of APS into SLE or lupus-like disease. Three 
studies involving 70 to 128 patients with APS found a variable rate of development of SLE 
over time: 
Zero percent at five years, 4 percent at 6.5 years, 13 percent at nine years. 
10.1.4 Mortality 
The presence of aPL in the serum of patients with SLE has been identified as an independent 
risk factor for premature death. There was an increased risk of premature death in patients 
with aPL, thrombocytopenia, and arterial occlusion. Other factors associated with 
premature death were the intensity of anticoagulation treatment, renal involvement, 
pleuritis, and disease activity. 
10.1.5 Management and recommendation  
Current therapies for the APS include the following medications: low molecular weight 
heparin , unfractionated heparin, warfarin, antiplatelet agents, aspirin , clopidogrel, 
hydroxychloroquine (see below). 
Initial approach to thrombosis: 
treatment for venous thromboembolic disease is part of the American Colleuge of Chest 
Physicians (ACCP) Evidence-Based Clinical Practice Guidelines (8th Edition), as the following:  
for patients with objectively confirmed deep vein thrombosis (DVT) or pulmonary 
embolism (PE), we recommend anticoagulant therapy with subcutaneous (SC) low-
molecular-weight heparin (LMWH), monitored IV, or SC unfractionated heparin (UFH), 
unmonitored weight-based SC UFH, or SC fondaparinux (all Grade 1A). For patients with a 
www.intechopen.com
 
Haematological Manifestations in Systemic Lupus Erythematosus 377 
high clinical suspicion of DVT or PE, we recommend treatment with anticoagulants while 
awaiting the outcome of diagnostic tests (Grade 1C).  
For patients with confirmed PE, we recommend early evaluation of the risks to benefits of 
thrombolytic therapy (Grade 1C); for those with hemodynamic compromise, we recommend 
short-course thrombolytic therapy (Grade 1B); and for those with nonmassive PE, we 
recommend against the use of thrombolytic therapy (Grade 1B). 
In acute DVT or PE, we recommend initial treatment with LMWH, UFH or fondaparinux for 
at least 5 days rather than a shorter period (Grade 1C); and initiation of vitamin K 
antagonists (VKAs) together with LMWH, UFH, or fondaparinux on the first treatment day, 
and discontinuation of these heparin preparations when the international normalized ratio 
(INR) is > or = 2.0 for at least 24 h (Grade 1A).  
For patients with DVT or PE secondary to a transient (reversible) risk factor, we recommend 
treatment with a VKA for 3 months over treatment for shorter periods (Grade 1A). For 
patients with unprovoked DVT or PE, we recommend treatment with a VKA for at least 3 
months (Grade 1A), and that all patients are then evaluated for the risks to benefits of 
indefinite therapy (Grade 1C).  
We recommend indefinite anticoagulant therapy for patients with a first unprovoked 
proximal DVT or PE and a low risk of bleeding when this is consistent with the patient's 
preference (Grade 1A), and for most patients with a second unprovoked DVT (Grade 1A). 
We recommend that the dose of VKA be adjusted to maintain a target INR of 2.5 (INR range, 
2.0 to 3.0) for all treatment durations (Grade 1A).  
For prevention of post-thrombotic syndrome (PTS) after proximal DVT, we recommend use 
of an elastic compression stocking (Grade 1A). For DVT of the upper extremity, we 
recommend similar treatment as for DVT of the leg (Grade 1C). Selected patients with 
lower-extremity (Grade 2B) and upper-extremity (Grade 2C). DVT may be considered for 
thrombus removal, generally using catheter-based thrombolytic techniques. For extensive 
superficial vein thrombosis, we recommend treatment with prophylactic or intermediate 
doses of LMWH or intermediate doses of UFH for 4 weeks (Grade 1B). 
The optimal duration of anticoagulation for venous thromboembolic disease following a 
first event is uncertain. However, given the high likelihood of recurrence in the untreated 
patient and the potentially devastating nature of recurrent thromboembolic events, we 
recommend lifelong anticoagulation for patients with the APS (Grade 1B) [86-89].  
Prophylaxis of the asymptomatic patient 
In the absence of symptoms or a history of symptoms attributable to the APS, we do not 
recommend the use of aspirin as prophylaxis (Grade 2B). For patients with SLE and aPL but 
no APS manifestations, the combination of low-dose aspirin and hydroxychloroquine may 
be considered (Grade 2C)[80-89].  
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